Japan Animal Referral Medical, The Current Fiscal Year Ordinary Profit Revised Upward by 9%, Exceeded Record Profit Forecast, Dividend Revised Upward by 12 yen

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Fri Feb 14, 2025 12:00 pm JST Earnings

6039 Japan Animal Referral Medical Center Co.,Ltd. 【J-GAAP】

Earnings Report

Japan Animal Referral Medical Center Co.,Ltd. <6039> [TSE Growth] announced its financial results at noon (12:00) on February 14th. The consolidated ordinary profit for the cumulative third quarter of the fiscal year ending March 2025 (April to December) expanded 590 million yen, an increase 76.1% compared to the same period last year.

In addition, the full-year consolidated ordinary profit has been revised upward 8.8%, from the previous forecast of 625 million yen to 680 million yen (compared to 489 million yen in the previous period), increasing the growth rate from 27.8% to 39.1%. The company has further increased its previous forecast of record profits for the first time in two years.

Based on the full-year plan announced by the company after the upward revision, our estimate of the consolidated ordinary profit for the October to March period (2H) has been revised upward 20.1%, from the previous forecast of 274 million yen to 329 million yen (compared to 337 million yen in the same period of the previous year), and the declining rate is expected to decrease from 18.7% to 2.4%.

In light of the strong performance, the company has significantly increased its planned year-end lump-sum dividend for the current fiscal year from the original plan of 25 yen to 37 yen (compared to 20 yen in the previous period).

In the most recent three-month period, from October to December (3Q), the consolidated ordinary profit increased 30.6% from the same period last year, reaching 239 million yen. The operating profit margin rose from 16.4% in the same period last year to 17.5%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Dec, 2022	2,915	456	421	279	119.8	78.8	Feb 9, 2023	J-GAAP
Apr - Dec, 2023	3,115	345	335	220	80.2	68.5	Feb 8, 2024	J-GAAP
Apr - Dec, 2024	3,942	590	590	409	157.9	86.8	Feb 14, 2025	J-GAAP
YoY	+26.5%	+71.0%	+76.1%	+85.9%	+96.8%

Guidance Update

Second Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2024 Prev	2,251	275	274	198	76.6	25	Nov 7, 2024	J-GAAP
Oct - Mar, 2024 New	2,651	330	329	233	90.1	37	Feb 14, 2025	J-GAAP
Revision Rate	+17.8%	+20.0%	+20.1%	+17.7%	+17.7%

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2025 Prev	4,820	625	625	440	170.2	25	May 9, 2024	J-GAAP
Mar, 2025 New	5,220	680	680	475	183.8	37	Feb 14, 2025	J-GAAP
Revision Rate	+8.3%	+8.8%	+8.8%	+8.0%	+8.0%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2023	2,288	337	337	240	87.6	20	May 9, 2024	J-GAAP
Oct - Mar, 2024 Guidance	2,651	330	329	233	90.1	37	Feb 14, 2025	J-GAAP
YoY	+15.9%	-2.1%	-2.4%	-2.9%	+2.9%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2023	3,872	580	534	380	156.3	0	May 11, 2023	J-GAAP
Mar, 2024	4,270	496	489	337	123.0	20	May 9, 2024	J-GAAP
Mar, 2025 Guidance	5,220	680	680	475	183.8	37	Feb 14, 2025	J-GAAP
YoY	+22.2%	+37.1%	+39.1%	+40.9%	+49.4%

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	1,133	186	183	123	44.8	16.4	Feb 8, 2024	J-GAAP
Jan - Mar, 2024	1,155	151	154	117	42.7	13.1	May 9, 2024	J-GAAP
Apr - Jun, 2024	1,250	149	150	103	39.4	11.9	Aug 1, 2024	J-GAAP
Jul - Sep, 2024	1,319	201	201	139	53.7	15.2	Nov 7, 2024	J-GAAP
Oct - Dec, 2024	1,373	240	239	167	64.5	17.5	Feb 14, 2025	J-GAAP
YoY	+21.2%	+29.0%	+30.6%	+35.8%	+43.8%